Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra (PEN) disclosed an insider transaction by Director Harpreet Grewal. On 11/04/2025, the reporting person sold 186 shares of common stock at a price of $227.58 per share, coded as “S.” The filing notes the sale was made under a Rule 10b5-1 trading plan. Following the transaction, 8,516 shares are beneficially owned in direct form. The filing also states that a portion of these shares is subject to vesting.
Penumbra (PEN) reported stronger Q3 results with revenue of $354.7 million, up from $301.0 million a year ago, and net income of $45.9 million versus $29.5 million. Operating income rose to $48.8 million from $35.4 million as gross profit increased to $240.4 million. Thrombectomy contributed $236.4 million and Embolization & Access $118.3 million. U.S. sales were $275.0 million and international $79.7 million.
For the first nine months, revenue reached $1,018.3 million (from $879.1 million) and net income was $130.3 million compared to a loss of $19.7 million last year. Cash and cash equivalents were $321.0 million, with $149.3 million in marketable investments, and operating cash flow of $152.2 million year‑to‑date. The company is building a ~330,000 sq. ft. Costa Rica facility, expecting about $35 million in project costs plus $23 million of improvements; $28.3 million was paid through Q3. The board extended the remaining $100.0 million share repurchase authorization to December 31, 2025. The prior immersive healthcare wind‑down carried no new charges in 2025.
Penumbra, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated into other filings unless specifically referenced. The report was signed by CFO Maggie Yuen on November 5, 2025.
Penumbra, Inc. (PEN): Notice of proposed sale under Rule 144. A holder filed to sell 186 shares of Penumbra common stock through Fidelity Brokerage Services LLC, with an aggregate market value $42,329.88. The shares are listed on the NYSE, with an approximate sale date of 11/04/2025.
The securities to be sold were acquired on 09/30/2025 as a stock award from Penumbra in the amount of 186 shares. As context, Penumbra reported 38,999,129 shares outstanding. The filer also reported sales in the prior three months: 186 shares on 09/02/2025 for $50,627.34 and 186 shares on 10/02/2025 for $46,241.46.
Penumbra (PEN) reported an insider transaction by its President, Shruthi Narayan. On 10/15/2025, 1,294 shares of common stock were withheld at $252.61 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units.
Following the transaction, the reporting person beneficially owned 26,961 shares directly. The filing notes that a portion of these shares is subject to vesting.
Penumbra (PEN) director Harpreet Grewal reported a sale of common stock. On 10/02/2025, the reporting person sold 186 shares at $248.61 per share under a Rule 10b5-1 trading plan. Following the transaction, the filer directly beneficially owned 8,702 shares. A portion of these shares is subject to vesting.
Johanna Roberts, EVP, General Counsel & Secretary of Penumbra Inc (PEN), reported multiple open-market sales executed 10/01/2025 under a Rule 10b5-1 trading plan. The transactions total 600 shares sold in separate blocks at weighted-average prices reported per block (ranging across the disclosures). Following these disposals, Ms. Roberts' beneficial ownership is reported as 64,257 shares. The Form 4 is signed and dated 10/03/2025. The filing notes that a portion of the shares sold were subject to vesting and that the filer will provide trade-level details upon request.
Penumbra Inc. (PEN) director Thomas C. Wilder reported a sale of 186 shares of common stock on 10/01/2025 at a price of $253.93 per share. The filing states the sale was executed under the reporting person’s Rule 10b5-1 trading plan. After the sale the report shows the reporting person beneficially owns 186 shares directly and 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006. The filing also notes that a portion of the reported shares are subject to vesting.
The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilder on 10/03/2025. No options, derivative transactions, earnings figures, or other corporate actions are disclosed in this form; it records a single small open-market sale and the current direct and indirect holdings disclosed by the reporting person.
Form 144 filed for Penumbra, Inc. (PEN) reports a proposed sale of 186 shares of Common Stock through Fidelity Brokerage Services LLC (Boston, MA) with an aggregate market value of $46,241.46 and an approximate sale date of 10/02/2025. The shares were acquired as a stock award from Penumbra, Inc. on 06/30/2025. The filer also reported a sale of 186 shares on 09/02/2025 with gross proceeds of $50,627.34. The filing names the seller as Grewal Harpreet (c/o Penumbra).
Form 144 notice for Penumbra, Inc. (PEN) reporting proposed sale of common stock. The filing shows 1,800 shares to be sold through J.P. Morgan Securities LLC with an aggregate market value of 455,796, and the approximate sale date listed as 10/01/2025 on the NYSE. The shares were acquired on 12/28/2022 by option exercise and paid in cash. The filer recorded prior sales in the past three months: 600 shares on 08/11/2025 for 143,361.60 and 600 shares on 09/02/2025 for 162,345.63. The filing includes a representation that the seller does not possess undisclosed material adverse information.